A cosmetic composition comprising oligo-, tetra- and hexapeptides

Abstract

Disclosed is a cosmetic composition comprising (a) oligopeptide selected from oligopeptide-1, palmitoyl oligopeptide-1, acetyl oligopeptide-1, myristoyl oligopeptide-1, or a combination thereof; (b) tetrapeptide selected from tetrapeptide-9, acetyl tetrapeptide-9, palmitoyl tetrapeptide-9, myristoyl tetrapeptide-9, or a combination thereof; and (c) hexapeptide selected from hexapeptide-11, acetyl hexapeptide-11, palmitoyl hexapeptide-11, myristoyl hexapeptide- 11, or a combination thereof.

Description

[0001] A COSMETIC COMPOSITION COMPRISING OLIGO-, TETRA- AND HEXAPEPTIDES

[0002] Field of the Invention

[0003] The present invention relates to a cosmetic composition comprising oligopeptide, tetrapeptide, and hexapeptide for providing enhanced anti-aging benefit.

[0004] Background of the Invention

[0005] The skin is a primary barrier of the human body. It protects the organs in the body from external stimulations. It is subject to intrinsic aging and extrinsic aging. Skin aging is a complex process, and alterations in human skin due to aging have distinct characteristics as compared to other organs. Characteristics of intrinsic or chronological skin aging include dryness, visible free lines and wrinkles, uneven skin pigmentation, loss of elasticity and skin sagging. Extrinsic factors including exposure to sunlight, pollutants and cigarette smoke can accelerate the skin aging process, especially on the face.

[0006] One of the main causes of skin aging is the degradation of collagen and elastin, which are the major components of the extracellular matrix that provides structural support and mechanical strength to the skin. Lumican is a small leucine-rich proteoglycan that is involved in the regulation of collagen fibrillogenesis and the organization of the extracellular matrix. Matrix metalloproteinases, are proteases that are capable of dissolving peptide bonds, thereby degrading the collagen. Upregulating the expression of lumican genes, promoting the production of collagen, or reducing the matrix metalloproteinases typically leads to an enhanced anti-aging benefit.

[0007] Therefore, the present inventors have recognized that there are still needs to further develop solution for anti-aging through upregulating the expression of lumican gene, promoting the production of collagen, and / or reducing the matrix metalloproteinases. It was surprisingly found that it is capable of providing improved anti-aging benefit by including oligopeptide, tetrapeptide, and hexapeptide into cosmetic composition according to the present invention.

[0008] Summary of the Invention

[0009] In a first aspect, the present invention is directed to a cosmetic composition comprising (a) oligopeptide selected from oligopeptide-1 , palmitoyl oligopeptide-1 , acetyl oligopeptide-1 , myristoyl oligopeptide-1 , or a combination thereof; (b) tetrapeptide selected from tetrapeptide-9, acetyl tetrapeptide-9, palmitoyl tetrapeptide-9, myristoyl tetrapeptide-9, or a combination thereof; and (c) hexapeptide selected from hexapeptide-11 , acetyl hexapeptide-11, palmitoyl hexapeptide-11, myristoyl hexapeptide-11, or a combination thereof.

[0010] In a second aspect, the present invention is directed to a method of providing benefit selected from the group consisting of enhancing collagen production in the skin, improving skin elasticity, reducing the appearance of wrinkles, reducing sagging, anti-aging, skin rejuvenation and upregulating the expression of lumican gene, or a combination thereof comprising the steps of applying a composition of the present invention on the desired surface.

[0011] In a third aspect, the present invention is directed to use of the cosmetic composition of the present invention for providing benefit selected from the group consisting of enhancing collagen production in the skin, improving skin elasticity, reducing the appearance of wrinkles, reducing sagging, anti-aging, skin rejuvenation and upregulating the expression of lumican gene.

[0012] All other aspects of the present invention will more readily become apparent upon considering the detailed description and examples which follow.

[0013] Detailed Description of the Invention

[0014] Except in the examples, or where otherwise explicitly indicated, all numbers in this description indicating amounts of material or conditions of reaction, physical properties of materials and / or use may optionally be understood as modified by the word “about”.

[0015] All amounts are by weight of the composition, unless otherwise specified.

[0016] It should be noted that in specifying any range of values, any particular upper value can be associated with any particular lower value.

[0017] For the avoidance of doubt, the word “comprising” is intended to mean “including” but not necessarily “consisting of” or “composed of’. In other words, the listed steps or options need not be exhaustive.

[0018] The disclosure of the invention as found herein is to be considered to cover all embodiments as found in the claims as being multiply dependent upon each other irrespective of the fact that claims may be found without multiple dependency or redundancy. Where a feature is disclosed with respect to a particular aspect of the invention (for example a composition of the invention), such disclosure is also to be considered to apply to any other aspect of the invention (for example a method of the invention) mutatis mutandis.

[0019] Preferably, the total amount of oligopeptide-1, palmitoyl oligopeptide-1, acetyl oligopeptide-1 , and myristoyl oligopeptide-1 is 0.000001 to 1%, more preferably 0.000004 to 0.5%, even more preferably 0.00001 to 0.2%, still even more preferably 0.00006% to 0.05%, and most preferably 0.0003 to 0.01% by weight of the total amount of the composition.

[0020] Preferably, the total amount of tetrapeptide-9, acetyl tetrapeptide-9, palmitoyl tetrapeptide-9, and myristoyl tetrapeptide-9 is 0.000001 to 1%, more preferably 0.0000003 to 0.5%, even more preferably 0.00001 to 0.2%, still even more preferably 0.00005% to 0.04%, and most preferably 0.00015 to 0.008% by weight of the total amount of the composition.

[0021] Preferably, the total amount of hexapeptide-11, acetyl hexapeptide-11, palmitoyl hexapeptide- 11, and myristoyl hexapeptide-11 is 0.000001 to 1%, more preferably 0.000003 to 0.5%, even more preferably 0.00001 to 0.2%, still even more preferably 0. 00005% to 0.04%, and most preferably 0.0002 to 0.008% by weight of the total amount of the composition.

[0022] Preferably, the weight ratio of total amount of oligopeptide-1, palmitoyl oligopeptide-1, acetyl oligopeptide-1, and myristoyl oligopeptide-1 to the total amount of tetrapeptide-9, acetyl tetrapeptide-9, palmitoyl tetrapeptide-9, and myristoyl tetrapeptide-9 is 1:100 to 100:1, more preferably 1 :30 to 30:1, even more preferably 1 :10 to 10:1, still even more preferably 1:3 to 3:1. Preferably, the weight ratio of total amount of oligopeptide-1, palmitoyl oligopeptide-1, acetyl oligopeptide-1, and myristoyl oligopeptide-1 to the total amount of hexapeptide-11, acetyl hexapeptide-11, palmitoyl hexapeptide-11, and myristoyl hexapeptide-11 is 1 :100 to 100:1, more preferably 1 :30 to 30:1, even more preferably 1 :10 to 10:1, still even more preferably 1:3 to 3:1.

[0023] Preferably, the weight ratio of total amount of tetrapeptide-9, acetyl tetrapeptide-9, palmitoyl tetrapeptide-9, and myristoyl tetrapeptide-9 to the total amount of hexapeptide-11, acetyl hexapeptide-11, palmitoyl hexapeptide-11, and myristoyl hexapeptide-11 is 1 :100 to 100:1, more preferably 1 :30 to 30:1, even more preferably 1 :10 to 10:1, still even more preferably 1:3 to 3:1. Alternatively, the weight ratio of total amount of oligopeptide-1, palmitoyl oligopeptide-1, acetyl oligopeptide-1, and myristoyl oligopeptide-1 to the total amount of tetrapeptide-9, acetyl tetrapeptide-9, palmitoyl tetrapeptide-9, and myristoyl tetrapeptide-9 is preferably 1 :30 to 300:1, more preferably 1 :10 to 100:1 , even more preferably 1 :3 to 30:1 , still even more preferably 1 :1 to 12:1. Preferably, the weight ratio of total amount of oligopeptide-1 , palmitoyl oligopeptide-1, acetyl oligopeptide-1 , and myristoyl oligopeptide-1 to the total amount of hexapeptide-11 , acetyl hexapeptide-11, palmitoyl hexapeptide-11, and myristoyl hexapeptide-11 is 1:25 to 200:1, more preferably 1 :12 to 90:1, even more preferably 1 :4 to 30:1 , still even more preferably 1 :1 to 9:1. Preferably, the weight ratio of total amount of tetrapeptide-9, acetyl tetrapeptide-9, palmitoyl tetrapeptide-9, and myristoyl tetrapeptide-9 to the total amount of hexapeptide-11, acetyl hexapeptide-11, palmitoyl hexapeptide-11, and myristoyl hexapeptide-11 is 1:135 to 54:1, more preferably 1 :45 to 18:1, even more preferably 1 :15 to 6:1 , still even more preferably 1 :5 to 2:1.

[0024] Preferably, the present invention provides a cosmetic composition comprising oligopeptide-1 , acetyl tetrapeptide-9 and hexapeptide-11.

[0025] Preferably, the amount of oligopeptide-1 is 0.000001 to 1%, more preferably 0.000004 to 0.5%, even more preferably 0.00001 to 0.2%, still even more preferably 0.00006% to 0.05%, and most preferably 0.0003 to 0.01% by weight of the total amount of the composition. Preferably, the amount of acetyl tetrapeptide-9 is 0.000001 to 1%, more preferably 0.0000003 to 0.5%, even more preferably 0.00001 to 0.2%, still even more preferably 0.00005% to 0.04%, and most preferably 0.00015 to 0.008% by weight of the total amount of the composition. Preferably, the amount of hexapeptide-11 is 0.000001 to 1%, more preferably 0.000003 to 0.5%, even more preferably 0.00001 to 0.2%, still even more preferably 0.00005% to 0.04%, and most preferably 0.0002 to 0.008% by weight of the total amount of the composition.

[0026] Preferably, the weight ratio of oligopeptide-1 to acetyl tetrapeptide-9 is 1:100 to 100:1, more preferably 1 :30 to 30:1, even more preferably 1 :10 to 10:1, still even more preferably 1:3 to 3:1. Preferably, the weight ratio of oligopeptide-1 to hexapeptide-11 is 1 :100 to 100:1, more preferably 1 :30 to 30:1, even more preferably 1 :10 to 10:1, still even more preferably 1:3 to 3:1. Preferably, the weight ratio of acetyl tetrapeptide-9 to hexapeptide-11 is 1:100 to 100:1, more preferably 1 :30 to 30:1, even more preferably 1 :10 to 10:1, still even more preferably 1:3 to 3:1.

[0027] Alternatively, the weight ratio of oligopeptide-1 to acetyl tetrapeptide-9 is 1:30 to 300:1, more preferably 1 :10 to 100:1 , even more preferably 1:3 to 30:1, still even more preferably 1:1 to 12:1. Preferably, the weight ratio of oligopeptide- 1 to hexapeptide- 11 is 1:25 to 200:1 , more preferably 1 :12 to 90:1, even more preferably 1 :4 to 30:1 , still even more preferably 1 :1 to 9:1. Preferably, the weight ratio of acetyl tetrapeptide-9 to hexapeptide- 11 is 1:135 to 54:1, more preferably 1 :45 to 18:1, even more preferably 1 :15 to 6:1 , still even more preferably 1 :5 to 2:1.

[0028] The composition preferably comprises a non-soap cleansing surfactant. The non-soap cleaning surfactant may be chosen from anionic, cationic, non-ionic, amphoteric surfactant and mixtures thereof. The preferred surface-active compounds that can be used are non-soap anionic, nonionic surfactant, amphoteric surfactant or a mixture thereof.

[0029] Suitable non-soap anionic surfactants include linear alkylbenzene sulphonate, primary and secondary alkyl sulphates, particularly Cs to C15 primary alkyl sulphates; alkyl ether sulphates; olefin sulphonates; alkyl xylene sulphonates; dialkyl sulphosuccinates; fatty acid ester sulphonates; or a mixture thereof. Sodium salts are generally preferred. Most preferred non- soap anionic surfactant are linear alkylbenzene sulphonate, particularly linear alkylbenzene sulphonates having an alkyl chain length of from Cs to C15. It is preferred if the level of linear alkylbenzene sulphonate is from 0 wt% to 30 wt%, more preferably from 1 wt% to 25 wt%, most preferably from 2 wt% to 15 wt%, by weight of the total composition.

[0030] Nonionic surfactants that may be used include the primary and secondary alcohol ethoxylates, especially the Cs to C20 aliphatic alcohols ethoxylated with an average of from 1 to 20 moles of ethylene oxide per mole of alcohol, and more especially the C10 to C15 primary and secondary aliphatic alcohols ethoxylated with an average of from 1 to 10 moles of ethylene oxide per mole of alcohol. Non ethoxylated nonionic surfactants include alkylpolyglycosides, glycerol monoethers, and polyhydroxyamides (glucamide). It is preferred if the level of non-ionic surfactant is from 0 wt% to 30 wt%, preferably from 1 wt% to 25 wt%, most preferably from 2 wt% to 15 wt%, by weight of a fully formulated composition comprising the microcapsules of the invention.

[0031] Suitable amphoteric surfactants preferably are betaine surfactants. Examples of suitable amphoteric surfactants include, but are not limited to, alkyl betaines, alkylamido betaines, alkyl sulfobetaines, alkyl sultaines and alkylamido sultaines; preferably, those having 8 to about 18 carbons in the alkyl and acyl group. It is preferred that the amount of the amphoteric surfactant is 0 to 20 wt%, more preferably from 1 to 10 wt%, by weight of the composition. It is also possible to include certain mono-alkyl cationic surfactants. Cationic surfactants that may be used include quaternary ammonium salts of the general formula R1R2R3R4N+X- wherein the R groups are long or short hydrocarbon chains, typically alkyl, hydroxyalkyl or ethoxylated alkyl groups, and X is a counter-ion (for example, compounds in which R1is a C8-C22 alkyl group, preferably a Cs-C or C12-C14 alkyl group, R2is a methyl group, and R3and R4, which may be the same or different, are methyl or hydroxyethyl groups); and cationic esters (for example, choline esters).

[0032] The composition may comprise water in amount of 10 to 95% by weight of the composition, more preferably from 45 to 92%, even more preferably from 52 to 90%, most preferably from 60% to 84% by weight of the composition. Alternatively, the composition may comprise water in amount of 35 to 99% by weight of the composition, more preferably from 50 to 99%, even more preferably from 70 to 97%, most preferably from 80% to 95% by weight of the composition.

[0033] The composition may comprise resorcinol derivative. Resorcinol derivative preferably refers to that at least one hydrogen on the ring structure and / or on a hydroxy group of the resorcinol replaced with an alkyl group or phenyl alkyl group. Preferably, the resorcinol derivative is 4- substituted resorcinol. Preferably, the resorcinol derivative is selected from 4-ethyl resorcinol, 4- butyl resorcinol, 4-hexyl resorcinol, phenylethyl resorcinol, or a mixture thereof, and more preferably, the resorcinol derivative comprises 4-hexyl resorcinol. The amount of the resorcinol derivative is preferably in the range of 0.00001 to 10%, more preferably from 0.001 to 5% and most preferably from 0.1 to 0.6% by weight of the total amount of the composition.

[0034] Preferably, the composition comprises Vitamin B3 compounds (including derivatives of vitamin B3). The vitamin B3 compounds comprises niacin, nicotinic acid, niacinamide or a mixture thereof. The most preferred vitamin B3 compound is niacinamide. Amount of Vitamin B3 compounds may be 0.1 to 10%, preferably 0.5 to 5% by weight of the composition.

[0035] The composition preferably additionally comprises one or more organic sunscreens. A wide variety of organic sunscreen is suitable for use in combination with the essential ingredients of this invention. Suitable IIV-A I IIV-B sunscreen include, 2- hydroxy-4-methoxybenzophenone, octyldimethyl p-aminobenzoic acid, digalloyltrioleate, 2,2-dihydroxy-4-methoxybenzophenone, ethyl-4-(bis(hydroxypropyl)) aminobenzoate, 2-ethylhexyl-2-cyano-3,3-diphenylacrylate, 2- ethylhexylsalicylate, glyceryl p-aminobenzoate, 3,3,5-trimethylcyclohexylsalicylate, methylanthranilate, p-dimethyl- aminobenzoic acid or aminobenzoate, 2-ethylhexyl-p-dimethyl- amino-benzoate, 2-phenylbenzimidazole-5-sulfonic acid, 2-(p-dimethylaminophenyl)-5- sulfonicbenzoxazoic acid, 2-ethylhexyl-p-methoxycinnamate, butylmethoxydibenzoylmethane, 2-hydroxy-4- methoxybenzophenone, octyldimethyl-p-aminobenzoic acid and mixtures thereof. The most suitable organic sunscreens are 2-ethylhexyl-p-methoxycinnamate, butylmethoxydibenzoylmethane or a mixture thereof. A safe and effective amount of organic sunscreen may be used in the compositions useful in the subject invention. The composition preferably comprises from 0.1% to 10%, more preferably from 0.1% to 5%, of organic sunscreen by weight of the composition.

[0036] Preferably, the composition comprises polyhydric alcohol. Polyhydric alcohols may be selected from group of glycerin, propylyene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1,3-butylene glycol, isoprene glycol, ethoxylated glycerol, propoxylated glycerol or a mixture thereof. Most preferred polyhydric alcohol is glycerol known also as glycerin. The amount of polyhydric alcohol may range anywhere from 0.1 to 20%, preferably 0.5 to 15% and more preferably 2 and 10% by weight of the composition.

[0037] Water-insoluble skin benefit agents may also be formulated into the compositions as conditioners and moisturizers. Examples include silicone oils; and vegetable triglycerides such as sunflower seed and cottonseed oils.

[0038] Some compositions may include thickeners. These may be selected from cellulosics, natural gums and acrylic polymers but not limited by this thickening agent types. Among the cellulosics are sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose and combinations thereof. Suitable gums include xanthan, pectin, karaya, agar, alginate gums and combinations thereof. Among the acrylic thickeners are homopolymers and copolymers of acrylic and methacrylic acids including carbomers such as Carbopol 1382, Carbopol 982, llltrez, Aqua SF-1 and Aqua SF-2 available from the Lubrizol Corporation. Amounts of thickener may range from 0.01 to 3% by weight of the active polymer (outside of solvent or water) in the compositions.

[0039] Preservatives can desirably be incorporated into the compositions of this invention to protect against the growth of potentially harmful microorganisms. Suitable traditional preservatives for compositions of this invention are alkyl esters of para-hydroxybenzoic acid. Other preservatives which have more recently come into use include hydantoin derivatives, propionate salts, and a variety of quaternary ammonium compounds. Particularly preferred preservatives are phenoxyethanol, methyl paraben, propyl paraben, imidazolidinyl urea, sodium dehydroacetate and benzyl alcohol. The preservatives should be selected having regard for the use of the composition and possible incompatibilities between the preservatives and other ingredients. Preservatives are preferably employed in amounts ranging from 0.01 % to 2% by weight of the composition.

[0040] A variety of other optional materials may be formulated into the compositions. These may include: antimicrobials such as 2-hydroxy-4,2’,4’-trichlorodiphenylether (triclosan), 2,6-dimethyl- 4-hydroxychlorobenzene, and 3,4,4’-trichlorocarbanilide; scrub and exfoliating particles such as polyethylene and silica or alumina; cooling agents such as menthol; skin calming agents such as aloe vera; and colorants.

[0041] In addition, the compositions of the invention may further include 0.5 to 10% by weight of sequestering agents, such as tetra sodium ethylenediaminetetraacetate (EDTA), EHDP or mixtures; opacifiers and pearlizers such as ethylene glycol distearate, titanium dioxide or Lytron 621 (Styrene / Acrylate copolymer); all of which are useful in enhancing the appearance or properties of the product.

[0042] The viscosity of the composition is preferably from 1 to 500 Pa s, more preferably from 5 to 150 Pa s, even more preferably from 10 to 60 Pa s, and most preferably from 20 to 40 Pa s. Viscosities as used herein were measured by a rheometer (Anton Paar Rheometer MCR501 , Austria) system with sandblasted parallel plate (PP50), with a plate-plate gap of 0.5 mm, at a shear rate of 10 s-1and at 25 °C. Preferably, the composition is an emulsion, more preferably an oil-in-water emulsion. Preferably the composition is a fluid liquid at 25 °C and atmospheric pressure.

[0043] Preferably, the cosmetic composition is a skin care composition. Skin care composition refers to a composition suitable for topical application to human skin, including leave-on and wash-off products but preferably leave-on compositions. The term “leave-on” as used with reference to compositions herein means a composition that is applied to or rubbed on the skin, and left thereon. The term “wash-off” as used with reference to compositions herein means a skin cleanser that is applied to or rubbed on the skin and rinsed off substantially immediately subsequent to application. The term "skin" as used herein includes the skin on the face, neck, chest, abdomen, back, arms, under arms, hands, and legs. Preferably “skin” means includes the skin on the face and under arms, more preferably skin means skin on the face other than lips. The composition is particularly preferably a moisturizer rather than a make-up product.

[0044] Preferably, the composition is a topical composition. Preferably, the composition may be in the form of cream, lotion, ointment, solution, suspension, toner, emulsion, paste, gel, powder, powder foundation, emulsion foundation, wax foundation, or spray. More preferably, the composition may be formulated in the form of cream, lotion, ointment, emulsion, gel, or a spray.

[0045] Preferably the use is non-therapeutic. Preferably the method is non-therapeutic. The term non- therapeutic typically means for cosmetic purposes and not curative or therapeutic purposes.

[0046] The following examples are provided to facilitate an understanding of the invention. The examples are not intended to limit the scope of the claims.

[0047] Example 1

[0048] This example demonstrates upregulation of lumican gene expression by peptide combination according to the present invention.

[0049] The gene expression of lumican different samples was evaluated following below procedures. Fibroblast L929 cells in logarithmic growth phase with good growth status were taken, seeded at a density of 1xio4cells / well in 48-well plates, and incubated overnight at 37° C with 5% CO2. Cells were treated according to Table 1 for 24 hours. After treatment, the total RNA for each sample was extracted using RNAprep Pure Plant Plus Kit (DP441 , Tiangen) according to manufacturer’s protocol.

[0050] The extracted RNA was reverse transcribed to generate the template cDNA using the PrimeScript kit. Amplification of target genes was performed with a HieffTM qPCR SYBR Green Master Mix on the ABI Vii 7 Real-Time PCR Systems (Applied Biosystems, Thermo fisher scientific, Carlsbad, CA, USA) with corresponding primers. The comparative Ct method was employed to calculate the relative quantification of gene expression. All samples were firstly normalized to the housekeeping gene, GAPDH, and then normalized with their related controls to obtain AACt values. The fold changes relative to the control were calculated (2A(-AACT)) and compared between treatments. All tests were conducted at least three times and Table 1 shows the fold changes in gene expression of lumican. Table 1

[0051] The level of actives is weight percentage based on the amount of medium. a: WKPep® Soligopeptide-PLUS, procured from Winkey Technology, China, b: WKPep® D-tide, procured from Winkey Technology, China. c: WKPep® Rpeptide, procured from Winkey Technology, China.

[0052] As evidenced in Table 1 , the fold change of 1 is significantly higher than the product of fold changes of A, B and C. Therefore, it was surprisingly found that the combination of Oligopeptide-1 , Acetyl Tetrapeptide-9, and Hexapeptide- 11 significantly upregulated the expression of lumican gene and therefore provided anti-aging associated benefit.

[0053] Example 2

[0054] This example demonstrates reduction of matrix metalloproteinase 1 (MMP1) by peptide combination according to the present invention.

[0055] The inhibition of MMP1 expression was tested by the following procedures. Human fibroblasts (Kunming Cell Bank, Chinese Academy of Sciences) in exponential growth phase, were added 0.25 wt% of trypsin digestive solution to detach the adherent cells. The cells cultured by PBS solution were irritated by UVB (80 mJ / cm2) for 15 minutes and then incubated in medium together with or without actives for 48 hours according to Table 2. After incubation, the level of MMP1 were obtained by using MMP-1 ELISA kit (IEBO, Item No.: E0097h) according to manufacturer’s protocol. The reduction times was calculated by (Level of MMP1 for control / Level of MMP1 for control). Each test was repeated three time and Table 2 shows the test results. Table 2

[0056] The level of actives is weight percentage based on the amount of medium.

[0057] As shown in Table 2, when combining three peptides, the reduction times of MMP1 (2) is high than the products of significantly lower than the product of reduction times of three single peptide (G, H, and I), or any product of reduction times of two peptide combination and the other single peptide (J and I, or K and H, or L and G). It was surprisingly found that the peptide combinations of the present invention provided synergistically better inhibition of MMP1 and therefore provided anti-aging benefit.

Claims

Claims1. A cosmetic composition comprising:(a) oligopeptide selected from oligopeptide-1 , palmitoyl oligopeptide-1 , acetyl oligopeptide- 1 , myristoyl oligopeptide-1 , or a combination thereof;(b) tetrapeptide selected from tetrapeptide-9, acetyl tetrapeptide-9, palmitoyl tetrapeptide-9, myristoyl tetrapeptide-9, or a combination thereof; and(c) hexapeptide selected from hexapeptide-11 , acetyl hexapeptide-11, palmitoyl hexapeptide-11, myristoyl hexapeptide-11, or a combination thereof, wherein the weight ratio of total amount of tetrapeptide-9, acetyl tetrapeptide-9, palmitoyl tetrapeptide-9, and myristoyl tetrapeptide-9 to the total amount of hexapeptide-11, acetyl hexapeptide-11 , palmitoyl hexapeptide-11, and myristoyl hexapeptide-11 is 1:100 to 100:1.

2. The composition according to claim 1 wherein the total amount of oligopeptide-1 , palmitoyl oligopeptide-1, acetyl oligopeptide-1, and myristoyl oligopeptide-1 is 0.000001 to 1%, preferably 0.0001% to 0.1% by weight of the total amount of the composition.

3. The composition according to claim 1 or 2 wherein the total amount of tetrapeptide-9, acetyl tetrapeptide-9, palmitoyl tetrapeptide-9, and myristoyl tetrapeptide-9 is 0.000001 to 1%, preferably 0.0001% to 0.1% by weight of the total amount of the composition.

4. The composition according to any one of the preceding claims wherein the total amount of hexapeptide-11, acetyl hexapeptide-11 , palmitoyl hexapeptide-11, and myristoyl hexapeptide-11 is 0.000001 to 1%, preferably 0.0001% to 0.1% by weight of the total amount of the composition.

5. The composition according to any one of the preceding claims wherein the weight ratio of total amount of oligopeptide-1, palmitoyl oligopeptide-1 , acetyl oligopeptide-1 , and myristoyl oligopeptide-1 to the total amount of tetrapeptide-9, acetyl tetrapeptide-9, palmitoyl tetrapeptide-9, and myristoyl tetrapeptide-9 is 1 :100 to 100:1, preferably 1:10 to 10:1.

6. The composition according to any one of the preceding claims wherein the weight ratio of total amount of oligopeptide-1, palmitoyl oligopeptide-1 , acetyl oligopeptide-1 , and myristoyl oligopeptide-1 to the total amount of hexapeptide-11, acetyl hexapeptide-11 , palmitoyl hexapeptide-11, and myristoyl hexapeptide-11 is 1:100 to 100:1 , preferably 1 :10 to 10:1.

7. A cosmetic composition comprising oligopeptide-1, acetyl tetrapeptide-9 and hexapeptide- 11.

8. The composition according to any one of the preceding claims wherein the amount of oligopeptide-1 is 0.000001 to 1%, preferably 0.00006% to 0.05% by weight of the total amount of the composition.

9. The composition according to any one of the preceding claims wherein the amount of acetyl tetrapeptide-9 is 0.000001 to 1%, preferably 0.00005% to 0.04% by weight of the total amount of the composition.

10. The composition according to any one of the preceding claims wherein the amount of hexapeptide-11 is 0.000001 to 1%, preferably 0.00005% to 0.04% by weight of the total amount of the composition.

11. The composition according to any one of the preceding claims wherein the weight ratio of oligopeptide-1 to acetyl tetrapeptide-9 is 1:30 to 300:1 , preferably 1:3 to 30:1.

12. The composition according to any one of the preceding claims wherein the weight ratio of oligopeptide-1 to hexapeptide-11 is 1:25 to 200:1, more preferably 1 :4 to 30:1.

13. The composition according to any one of the preceding claims wherein the composition is an emulsion, preferably an oil-in-water emulsion.

14. A method of providing benefit selected from the group consisting of enhancing collagen production in the skin, improving skin elasticity, reducing the appearance of wrinkles, reducing sagging, anti-aging, skin rejuvenation and upregulating the expression of lumican gene, or a combination thereof comprising the steps of applying a composition any one of the preceding claims 1 to 13 on the desired surface.

15. Use of the cosmetic composition according to any one of the preceding claims 1 to 13 for providing benefit selected from the group consisting of enhancing collagen production in the skin, improving skin elasticity, reducing the appearance of wrinkles, reducing sagging, antiaging, skin rejuvenation and upregulating the expression of lumican gene.